Wednesday, July 16, 2025 7/16/2025

Behavioral Smoking Cessation Treatment for People Living with HIV/AIDS

Award Number: R01DA034537
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2013
PERIOD OF PERFORMANCE END DATE: 07/31/2019

Group Awards By:

View Award Description

Behavioral Smoking Cessation Treatment for People Living with HIV/AIDS - DESCRIPTION (provided by applicant): Approximately 50% to 70% of people living with Human Immunodeficiency Virus (HIV)/Autoimmune Deficiency Syndrome (AIDS; PLWHA) are nicotine dependent smokers, and thus at increased risk for smoking-related morbidity and mortality. Effective smoking cessation strategies are urgently needed to reduce both the health burden of smoking on PLWHA and costs to society. Contingency management (CM) treatments are efficacious in reducing cigarette smoking in other populations, but to date there are no published studies on the use of CM for smoking cessation in PLWHA. PLWHA who smoke cigarettes will be recruited from a large urban HIV/AIDS treatment clinic. All participants will receive bupropion treatment for 12 weeks. In Phase 1 (weeks 1-4), participants will be randomly assigned to: 1) Brief counseling and bupropion treatment based on standard of care (SoC); or 2) SoC plus brief, high-magnitude prize reinforcement (CM) designed to enhance initiation of abstinence by providing prize incentives. In Phase 2 (weeks 5-12) we will then use a stepped care model to assign participants to a tailored treatment intervention based on whether they respond adequately to the treatment in Phase 1. Non-responders will be randomly assigned to one of two 8-week behavioral treatments: 1) continued weekly counseling and monitoring of smoking; or 2) continued counseling plus prize CM. Treatment responders will be randomly assigned to: 1) no additional behavioral treatment (consistent with SoC); or 2) 8-weeks of counseling and monitoring, plus low-magnitude prize CM. Smoking will be assessed at pre-treatment baseline, during treatment phases, and at 6- and 12-month follow-up points. Outcome measures during treatment will include longest duration of continuous abstinence and biologically verified reduction in smoking (cotinine and expired carbon monoxide). Long-term outcomes will include 7-day point-prevalence of cigarette smoking at each follow-up. We predict CM patients will reduce cigarette smoking more than non-CM conditions in each treatment phase. This study is highly innovative as it is the first to examine the use of CM and to use a stepped care model for smoking cessation among PLWHA. Tailoring smoking cessation treatment on the basis of patient outcome early in treatment may improve smoking cessation effectiveness, and ultimately may reduce healthcare costs and improve the overall health of PLWHA. Thus this project has a high public health significance.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = -$145,879 )
2020	2016	WAYNE STATE UNIVERSITY	5057 WOODWARD STE 13001	DETROIT	MI	48202	WAYNE	USA	Drug Use and Addiction Research Programs	000	4	1/6/2020	EXTENSION WITH OR WITHOUT FUNDS	-$145,879
														Subtotal = -$145,879

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2016	WAYNE STATE UNIVERSITY	5057 WOODWARD 13 FLOOR	DETROIT	MI	48202	WAYNE	USA	Drug Use and Addiction Research Programs	000	4	7/11/2018	EXTENSION WITH OR WITHOUT FUNDS	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2016	WAYNE STATE UNIVERSITY	5057 WOODWARD 13 FLOOR	DETROIT	MI	48202	WAYNE	USA	Drug Use and Addiction Research Programs	001	4	1/6/2017	EXTENSION WITH OR WITHOUT FUNDS	$403,750
2017	2015	WAYNE STATE UNIVERSITY	5057 WOODWARD 13 FLOOR	DETROIT	MI	48202	WAYNE	USA	Drug Use and Addiction Research Programs	000	3	1/6/2017	NON-COMPETING CONTINUATION	-$403,750
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $447,261 )
2016	2016	WAYNE STATE UNIVERSITY	5700 CASS SUITE 4602	DETROIT	MI	48202	WAYNE	USA	Drug Use and Addiction Research Programs	000	4	7/29/2016	EXTENSION WITH OR WITHOUT FUNDS	$447,261
														Subtotal = $447,261

Issue Date FY: 2015 ( Subtotal = $445,004 )
2015	2015	WAYNE STATE UNIVERSITY	5700 CASS SUITE 4602	DETROIT	MI	48202	WAYNE	USA	Drug Use and Addiction Research Programs	000	3	7/20/2015	NON-COMPETING CONTINUATION	$445,004
														Subtotal = $445,004

Issue Date FY: 2014 ( Subtotal = $451,779 )
2014	2014	WAYNE STATE UNIVERSITY	5700 CASS SUITE 4602	DETROIT	MI	48202	WAYNE	USA	Drug Use and Addiction Research Programs	000	2	7/3/2014	NON-COMPETING CONTINUATION	$451,779
														Subtotal = $451,779

Issue Date FY: 2013 ( Subtotal = $454,307 )
2013	2013	WAYNE STATE UNIVERSITY	5700 CASS SUITE 4602	DETROIT	MI	48202	WAYNE	USA	Drug Use and Addiction Research Programs	000	1	8/8/2013	NEW	$454,307
														Subtotal = $454,307

Grand Total All Awards = $1,652,472

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Behavioral Smoking Cessation Treatment for People Living with HIV/AIDS

Award Number: R01DA034537

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2013

PERIOD OF PERFORMANCE END DATE: 07/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer